此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Near Vergence Training for Distance Control in Intermittent Exotropia

2026年9月23日 更新者:LEUNG Tsz Wing、The Hong Kong Polytechnic University

Evaluating Near Vergence Training for Distance Control in Basic and Divergence Excess Intermittent Exotropia

Intermittent Exotropia (IXT) is a common type of eye misalignment where one eye periodically turns outward, and control is typically much worse when looking at objects far away than close up. However, most currently available training programme are focused on near-viewing tasks. The goal of this clinical trial is to investigate if a new, structured, home-based near eye training program works to improve distance eye alignment control in children and young adults with IXT.

The main questions the study aims to answer are:

  • Does a 12-week near eye training program improve a participant's ability to control their eye alignment when looking at a distance?
  • Does using a special reading glasses during near training help to control distance eye alignment better than doing the training without the reading glasses?
  • Do the benefits of this eye training last after the training has stopped?

This is a two- phase, single- masked (examiner masked), randomized clinical trial with crossover design. The entire study duration is about 24 weeks. A total sample size of 42 participants, aged 6 to 25 years with diagnosed Basic (distance deviation is within 10 prism diopters of the near deviation) or Divergence excess (distance deviation is at least 10 prism diopters greater than the near deviation) IXT, will be recruited.

In Phase I (Weeks 0 to 12), participants will be randomly allocated into one of three groups, with 14 individuals in each group:

  • Group 1 does eye training while wearing special plus-power reading glasses that remove the need to focus up close, mimicking how the eyes look at a distance.
  • Group 2 does the exact same eye training but wears regular distance glasses without the special reading addition.
  • Group 3 serves as a control group that does not do training during the first 12 weeks, but will receive the training in the second phase.

In Phase II (Weeks 13 to 24), which is a crossover phase, groups 1 and 2 will stop training to see if the visual improvements last, while group 3 will be re-randomized into two subgroups (group 3A, with special plus-power reading glasses, and group 3B with regular glasses with distance correction) that will undertake daily eye training for 12 weeks to ensure ethical treatment access. All participants will have a final eye exam at 24 weeks.

During home training, participants will:

  • Wear standard glasses provided by the study.
  • Practice daily, home-based eye exercises for 12 weeks using a standardized software program on a computer or tablet.
  • Complete 3 training sessions every day, lasting 7 minutes per session.
  • Wear red-blue 3D glasses during training and press arrow keys or swipe the screen to play a visual game that dynamically changes in difficulty.

Preliminary test and binocular vision assessment with fixed and uniform sequence will be performed at baseline visit, 6th week interim visit, 12th and 24th week evaluation. All eye examinations will be carried out in The Optometry Centre (A034), the School of Optometry, The Hong Kong Polytechnic University.

The following data will be statistically analyzed. The primary outcome data is distance Office Control Score (OCS) at 12-week visit. Secondary outcomes data include change in deviation angle, near and distance stereopsis and patient- / parent- reported health-related quality-of-life questions at 12-week.

研究概览

研究类型

介入性

注册 (估计的)

42

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Horace Ho-yin Wong, MClinOptom, BSc (Hons) Optom
  • 电话号码:852-63384048
  • 邮箱:horace.wong@polyu.edu.hk

研究联系人备份

学习地点

      • Hong Kong、香港
        • 招聘中
        • The Optometry Clinic, The Hong Kong Polytechnic University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 至 25年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

  • Age and Diagnosis: Participants must be aged 6 to ≤ 25 years at the time of screening, with a confirmed clinical diagnosis of either Basic or Divergence Excess (DE) Intermittent Exotropia (IXT).

  • Ocular Alignment Magnitude: Distance exodeviation measuring between 10 and 40 prism diopters (pd) inclusive, determined by the prism and alternate cover test (PACT).

  • Distance-Near Disparity Limits: Near exodeviation must not exceed the distance exodeviation by more than 10 pd (to exclude Convergence Insufficiency type exotropia).

  • Baseline Distance Control: A baseline distance IXT Office Control Score (OCS) between Grade 2 and Grade 4 inclusive, based on the mean of 3 standardized assessments.

  • Baseline Near Control: A baseline near IXT control score less than or equal to the distance IXT control score, based on the mean of 3 standardized assessments.

  • Visual Acuity: Best-corrected visual acuity (BCVA) of Logarithm of the Minimum Angle of Resolution (logMAR) 0.1 or better in each eye at both distance and near fixation.

  • Sensory Status: Measurable near stereoacuity of 400 arc seconds or better on the Preschool Randot stereoacuity test.

  • Refractive Correction Stability: Compliance with wearing a stable, appropriate spectacle correction for ≥ 4 months prior to formal baseline assessment if the participant meets any of the following refractive thresholds:

    • Myopia < -0.50D spherical equivalent (SE) in either eye.
    • Hyperopia > +2.50D SE in either eye.
    • Anisometropia > 1.00 SE.
    • Astigmatism > 1.50D cylinder in either eye.
  • Treatment History: No history of prior non-surgical interventions for IXT, including patching, vision therapy/orthoptics, or overminus lens therapy (≥ 0.50 D).

  • Surgical History: No prior history of strabismus surgery, extraocular muscle botulinum toxin injections, intraocular surgery, or refractive surgery.

  • Trial Commitment: No planned strabismus surgery or conflicting ocular therapies during the 24-week study period.

Exclusion Criteria

  • Amblyopia and Co-morbid Strabismus: Presence of amblyopia, nystagmus, restrictive strabismus, or paretic strabismus.
  • Vertical Misalignment: Presence of an associated vertical ocular deviation > 5 pd.
  • Significant Pathologies: Co-existing significant ocular disease or neurological disorders (e.g., cerebral palsy) that could confound oculomotor or sensory evaluations.
  • Confounding Medications: Regular use of systemic or topical ocular medications known to alter accommodative or vergence function within the 3 months prior to screening (including, but not limited to, atropine, pirenzepine, or systemic anti-epileptic agents).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:Active training group with reading glasses

Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence

Standardized home-based near vergence training platform with data visualization tools and communication platforms

有源比较器:Active training group without reading glasses

Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence

Standardized home-based near vergence training platform with data visualization tools and communication platforms

无干预:Control group

No training will be received in Phase I (Weeks 0 to 12); Will receive training in Phase II of the study (Weeks 13 to 24) to ensure ethical treatment access

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change of Distance Office Control Score
大体时间:Baseline, 6-week, 12-week and 24-week

Objective and quantitative office control scale, based on the frequency of deviation and the recovery speed followed by occlusion. Ranged from 0 to 5, with score 0 represents the best control (phoria with excellent control), and score 5 represents the worst control (constant exotropia during the 30-second observation)

Baseline, 6-week, 12-week and 24-week

次要结果测量

结果测量
措施说明
大体时间
Change of exodeviation magnitude angle
大体时间:Baseline, 6-week, 12-week and 24-week

measured by Prism and Alternate Cover Test, ranged from 1 to 50 prism diopter. The higher the value, the worse is the magnitude angle of the exodeviation

Baseline, 6-week, 12-week and 24-week
Change of Distance stereoacuity
大体时间:Baseline, 6-week, 12-week and 24-week

measured by Distance Randot® stereotest, ranged from 400 seconds of arc (the worst measurable stereoacuity) to 60 seconds of arc (the best measurable stereoacuity )

Baseline, 6-week, 12-week and 24-week
Change of Near stereoacuity
大体时间:Baseline, 6-week, 12-week and 24-week

measured by Preschool Randot® stereoacuity test, ranged from 800 seconds of arc (the worst measurable stereoacuity) to 40 seconds of arc (the best measurable stereoacuity )

Baseline, 6-week, 12-week and 24-week
Change of Quality of Life (QoL) measures - Chinese Intermittent Exotropia Questionnaire (CIXTQ) for children aged 5 to 17 and parents of children aged 2 to 17
大体时间:Baseline, 12-week and 24-week

Part a: Child CIXTQ - 12 items completed by children, simplified 3-point scale (0, 50 and 100); Part b: Proxy CIXTQ - 12 items completed by parents to evaluate their child's health-related quality-of-life (HRQoL) from a parental perspective, 5-point Likert-type (0, 25, 50, 75, and 100); Part c: Parent CIXTQ - 17 items to measure the parent's own HRQoL, 5-point Likert-type (0, 25, 50, 75 and 100). The higher the score, the better the outcome (QoL).

Baseline, 12-week and 24-week
Change of Quality of Life (QoL) measures - The Chinese Adult Strabismus Quality of Life Questionnaire (CAS-20) for adult participants aged 18 or above
大体时间:Baseline, 12-week and 24-week

20 items to assess psychosocial impact and visual function, 5-point Likert-type (0, 25, 50, 75 and 100). Higher scores indicating better perceived QoL.

Baseline, 12-week and 24-week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月10日

初级完成 (估计的)

2028年6月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年6月3日

首先提交符合 QC 标准的

2026年6月10日

首次发布 (实际的)

2026年6月11日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • HSEARS20251213004

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅